Regenxbio(NASDAQ) RGNX

Market Cap$793.48M

Since IPO (2015)-61%

5 Year-59%

1 Year+50%

1 Month+16%

Premium Feature

Moneyball Superscore

53/100

$11.08

-7.82%

-0.94Today

After hours$11.05-$0.03 (-0.27%)

Regenxbio last closing stock price
Metric	Price	Date
Last close	USD 12.02	2026-08-19

Regenxbio stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+10.17%	USD 10.91	2026-08-12
1 month	+16.47%	USD 10.32	2026-07-20
3 month	+78.07%	USD 6.75	2026-05-21
Year to date	-16.53%	USD 14.40	2025-12-31
1 year	+49.69%	USD 8.03	2025-08-19
3 year	-31.9%	USD 17.65	2023-08-18
5 year	-59.43%	USD 29.63	2021-08-20
Since inception	-60.53%	USD 30.45	2015-09-17

Regenxbio Financials at a Glance

Market Cap

$793.48M

Revenue (TTM)

$174.48M

Net Income (TTM)

-$196.43M

EPS (TTM)

-$3.79

P/E Ratio

-3.18

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$11.08

Volume

947,264

Open

$11.98

Price

$11.08

Volume

947,264

Open

$11.98

Previous Close

$11.06

Daily Range

$11.03 - $12.08

52-Week Range

$5.46 - $16.19

Estimated Earnings Date

Nov 5, 2026

Dividend

$0.00

Beta (Volatility)

1.51 (High)

Price

$11.08

Volume

947,264

Open

$11.98

Previous Close

$11.06

Daily Range

$11.03 - $12.08

52-Week Range

$5.46 - $16.19

Estimated Earnings Date

Nov 5, 2026

RGNX News

Son holding father's hand at the hospital

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

Todd CampbellMay 24, 2019

3 Top Small-Cap Stocks to Buy Right Now

George Budwell, PhDMar 4, 2019

Page 1

RGNX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Regenxbio

REGENXBIO Inc. creates gene therapies to treat serious diseases with a single dose. These treatments help the body produce its own medicine to fix genetic problems. The company focuses on conditions that affect vision, muscles, and metabolism.

What Regenxbio Is Developing

Sura-vec: Investigational treatment for chronic eye conditions like wet age-related macular degeneration and diabetic retinopathy.
RGX-202: Potential therapy for Duchenne muscular dystrophy designed to help muscles resist damage.
RGX-121: Candidate for Hunter syndrome aiming to deliver a gene that produces a missing enzyme.
NAV Technology Platform: Proprietary delivery system used for internal programs and licensed to other biotechnology firms.

Strategic Partnerships and Milestones

Entered a collaboration with AbbVie in September 2021 to develop and commercialize sura-vec.
Partnered with Nippon Shinyaku in January 2025 for the development of therapies for certain rare metabolic diseases.
Earned a $100 million milestone payment from AbbVie in June 2026 for dosing the first patient in a pivotal clinical trial.
Planned a Biologics License Application submission for RGX-202 in the third quarter of 2026.

Proprietary Technology and Manufacturing

Regenxbio uses its proprietary NAV Technology Platform to deliver functional genes to specific cells. This platform is also licensed to third parties, generating royalty income from commercial products like Zolgensma.

Key Financial Results

Total revenue reached $108.0 million in the second quarter of 2026, up from $21.4 million in the second quarter of 2025.
Net income was $22.7 million for the second quarter of 2026 compared to a net loss of $70.9 million a year earlier.
Cash, cash equivalents, and marketable securities totaled $105.5 million as of June 30, 2026.
Royalties from Zolgensma and Itvisma were $8.9 million for the six-month period ended June 30, 2026.
License and royalty revenue increased by $85.4 million for the three-month period ended June 30, 2026.

Bottom Line

Regenxbio is moving from a research-focused firm toward potential commercial product launches. Its reliance on partnerships and its proprietary delivery platform provides multiple paths for development and revenue.

AI Generated • Aug 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

371

CEO

Curran M. Simpson

Website

www.regenxbio.com

Headquarters

Rockville, MD 20850, US

RGNX Financials

Key Financial Metrics (TTM)

Gross Margin

54.22%

Operating Margin

-94.08%

Net Income Margin

-112.58%

Return on Equity

-220.07%

Return on Capital

-44.38%

Return on Assets

-50.81%

Earnings Yield

-31.45%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$793.48M

Shares Outstanding

66.01M

Volume

947.26K

Avg. Volume

1.97M

Financials (TTM)

Gross Profit

$94.61M

Operating Income

-$164.15M

EBITDA

-$139.12M

Operating Cash Flow

-$246.67M

Capital Expenditure

-$2.99M

Free Cash Flow

-$249.67M

Cash & ST Invst.

$105.52M

Total Debt

$68.95M

Regenxbio Performance Analysis

Regenxbio annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 112,724,000	-76.0%
2023	2023-12-31	USD 90,242,000	-19.9%
2024	2024-12-31	USD 83,328,000	-7.7%
2025	2025-12-31	USD 170,441,000	104.5%

Regenxbio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	39.2%
Q4	2025-12-31	2.0%
Q1	2026-03-31	-78.9%
Q2	2026-06-30	1589.6%

Regenxbio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -6.50	N/A
2023	2023-12-31	USD -6.02	-7.3%
2024	2024-12-31	USD -4.59	-23.9%
2025	2025-12-31	USD -3.76	-18.0%

Regenxbio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	13.0%
Q4	2025-12-31	-8.3%
Q1	2026-03-31	-32.3%
Q2	2026-06-30	125.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$108.02M

+405.7%

Gross Profit

$106.98M

+773.6%

Gross Margin

99.04%

N/A

Market Cap

$793.48M

N/A

Market Cap/Employee

$2.14M

N/A

Employees

371

N/A

Net Income

$22.71M

+132.0%

EBITDA

$34.26M

+161.2%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$105.52M

-67.4%

Total Debt

$68.95M

-11.3%

Accounts Receivable

$106.75M

+396.9%

Inventory

$0.00

N/A

Long Term Debt

$61.60M

-11.6%

Short Term Debt

$7.36M

-8.6%

Return on Assets

-50.81%

N/A

Return on Invested Capital

-54.00%

N/A

Free Cash Flow

-$63.00M

-26.7%

Operating Cash Flow

-$62.24M

-26.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

FDMT4D Molecular Therapeutics, Inc.

FDMT4D Molecular Therapeutics, Inc.$16.10-3.94%

OLMAOlema Pharmaceuticals, Inc.

OLMAOlema Pharmaceuticals, Inc.$10.90-3.63%

VSTMVerastem, Inc.

VSTMVerastem, Inc.$6.82-6.51%

VTYXVentyx Biosciences, Inc.

VTYXVentyx Biosciences, Inc.$14.00+0.00%

PRTAProthena Corporation plc

PRTAProthena Corporation plc$9.03-2.80%

CRVSCorvus Pharmaceuticals, Inc.

CRVSCorvus Pharmaceuticals, Inc.$14.33-6.95%

MLTXMoonLake Immunotherapeutics

MLTXMoonLake Immunotherapeutics$15.87-5.20%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$9.81+0.06%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$134.00-0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$8.88-0.03%

IBITiShares Bitcoin Trust

IBITiShares Bitcoin Trust$41.20+0.06%

MRNAModerna

MRNAModerna$133.32-0.24%

NVDANvidia

NVDANvidia$216.85-0.00%

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF

ETHAiShares Ethereum Trust - iShares Ethereum Trust ETF$17.55+0.11%

Questions About RGNX

What is the current price of Regenxbio?

Regenxbio is trading at $11.06 per share.

What is the 52-week range for Regenxbio?

Over the past 52 weeks, Regenxbio has traded between $5.46 and $16.19.

How much debt does Regenxbio have?

As of the most recent reporting period, Regenxbio reported total debt of $250.46M.

How much cash does Regenxbio have on hand?

Regenxbio reported $36.71M in cash and cash equivalents in its most recent financial results.

What is Regenxbio’s dividend yield?

Regenxbio does not currently have a dividend yield.

Regenxbio(NASDAQ) RGNX

Regenxbio Financials at a Glance

RGNX News

Does an FDA Fast Track Designation Make Regenxbio Stock a Buy Now?

3 Small-Cap Medical Stocks With Big Momentum

Why Regenxbio Stock Is Way Up Today

Big Pharma Has Mad Love For These 2 Biotechs

3 Blindness-Fighting Biotech Stocks That Could Surge This Week

3 Top Biotech Stocks to Buy Right Now

Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio

3 Top Small-Cap Stocks to Buy Right Now

RGNX: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Regenxbio

What Regenxbio Is Developing

Strategic Partnerships and Milestones

Proprietary Technology and Manufacturing

Key Financial Results

Bottom Line

RGNX Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Regenxbio Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About RGNX

What is the current price of Regenxbio?

What is the 52-week range for Regenxbio?

How much debt does Regenxbio have?

How much cash does Regenxbio have on hand?

What is Regenxbio’s dividend yield?

Premium Investing Services